AU6829287A – Stabilised formulations of alpha-interferon
– Google Patents
AU6829287A – Stabilised formulations of alpha-interferon
– Google Patents
Stabilised formulations of alpha-interferon
Info
Publication number
AU6829287A
AU6829287A
AU68292/87A
AU6829287A
AU6829287A
AU 6829287 A
AU6829287 A
AU 6829287A
AU 68292/87 A
AU68292/87 A
AU 68292/87A
AU 6829287 A
AU6829287 A
AU 6829287A
AU 6829287 A
AU6829287 A
AU 6829287A
Authority
AU
Australia
Prior art keywords
active ingredient
alpha
interferon
ifn alpha
stabilised formulations
Prior art date
1986-02-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU68292/87A
Other versions
AU601712B2
(en
Inventor
Helmut Dr. Franz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-02-05
Filing date
1987-02-04
Publication date
1987-08-06
1987-02-04
Application filed by Dr Karl Thomae GmbH
filed
Critical
Dr Karl Thomae GmbH
1987-08-06
Publication of AU6829287A
publication
Critical
patent/AU6829287A/en
1990-09-20
Application granted
granted
Critical
1990-09-20
Publication of AU601712B2
publication
Critical
patent/AU601712B2/en
2007-02-04
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
A61K38/19—Cytokines; Lymphokines; Interferons
A61K38/21—Interferons [IFN]
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
A61K38/19—Cytokines; Lymphokines; Interferons
A61K38/21—Interferons [IFN]
A61K38/212—IFN-alpha
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K47/38—Cellulose; Derivatives thereof
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K9/00—Medicinal preparations characterised by special physical form
A61K9/0012—Galenical forms characterised by the site of application
A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Abstract
The pharmaceutical forms are intended for topical administration and employ as vehicle for and stabiliser of the active ingredient a composition which specifically confers special stability on the active ingredient IFN alpha. The forms are essentially composed of hydroxyethylcellulose and gelatin and preferably contain highly purified IFN alpha which has been prepared by DNA recombination as active ingredient.
AU68292/87A
1986-02-05
1987-02-04
Stabilised formulations of alpha-interferon
Ceased
AU601712B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
DE3603444
1986-02-05
DE19863603444
DE3603444A1
(en)
1986-02-05
1986-02-05
PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA
Publications (2)
Publication Number
Publication Date
AU6829287A
true
AU6829287A
(en)
1987-08-06
AU601712B2
AU601712B2
(en)
1990-09-20
Family
ID=6293372
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU68292/87A
Ceased
AU601712B2
(en)
1986-02-05
1987-02-04
Stabilised formulations of alpha-interferon
Country Status (20)
Country
Link
EP
(1)
EP0231816B1
(en)
JP
(1)
JPS62209024A
(en)
KR
(1)
KR870007698A
(en)
AT
(1)
ATE63823T1
(en)
AU
(1)
AU601712B2
(en)
CA
(1)
CA1295242C
(en)
DD
(1)
DD284602A5
(en)
DE
(2)
DE3603444A1
(en)
DK
(1)
DK164202C
(en)
ES
(1)
ES2028796T3
(en)
FI
(1)
FI86144C
(en)
GR
(1)
GR3002270T3
(en)
HU
(1)
HU196560B
(en)
IE
(1)
IE59697B1
(en)
IL
(1)
IL81472A0
(en)
NO
(1)
NO169638C
(en)
NZ
(1)
NZ219169A
(en)
PH
(1)
PH24377A
(en)
PT
(1)
PT84243B
(en)
ZA
(1)
ZA87793B
(en)
Cited By (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU615473B2
(en)
*
1987-09-17
1991-10-03
Boehringer Ingelheim International Gmbh
Stabilisation of therapeutically active proteins in a pharmaceutical composition
WO1993006856A1
(en)
*
1991-10-11
1993-04-15
Mark Cedric Gillies
Treating ophthalmic fibrosis using interferon-alpha
US5863530A
(en)
*
1991-10-11
1999-01-26
Spruson & Ferguson
Treating ophthalmic fibrosis using interferon-α
Families Citing this family (21)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US5275804A
(en)
*
1986-02-25
1994-01-04
E. B. Michaels Research Associates, Inc.
Process and composition for oral hygiene
US5266310A
(en)
*
1987-09-17
1993-11-30
Boehringer Ingelheim International Gmbh
Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3803312A1
(en)
*
1988-02-04
1989-08-10
Gerd Prof Dr Med Gross
Use of an interferon-containing gel
NO179479C
(en)
*
1988-03-11
1996-10-16
Teikoku Seiyaku Kk
Process for the preparation of an intravaginal pharmaceutical preparation
WO1989010756A1
(en)
*
1988-05-06
1989-11-16
Toray Industries, Inc.
STABLE INTERFERON beta COMPOSITION
US5389676A
(en)
*
1991-03-22
1995-02-14
E. B. Michaels Research Associates, Inc.
Viscous surfactant emulsion compositions
US5244652A
(en)
*
1991-03-22
1993-09-14
E. B. Michaels Research Associates, Inc.
Viscous surface active composition
US6630168B1
(en)
1997-02-20
2003-10-07
Biomedicines, Inc.
Gel delivery vehicles for anticellular proliferative agents
FI106465B
(en)
*
1998-06-10
2001-02-15
Suomen Punainen Risti Veripalv
A process for preparing virus-safe pharmaceutical compositions
US6923966B2
(en)
1999-04-08
2005-08-02
Schering Corporation
Melanoma therapy
JP4536194B2
(en)
*
2000-02-17
2010-09-01
大日本住友製薬株式会社
Stable injectable formulation
ES2357474T3
(en)
*
2000-03-07
2011-04-26
Rush-Presbyterian-St.Luke’s Medical Center
COMPOSITIONS AND ITS USE TO CATCH AND INACTIVATE PATHOGEN MICROBES AND SpermATOZIODS.
US6328987B1
(en)
*
2000-11-03
2001-12-11
Jan Marini Skin Research, Inc.
Cosmetic skin care compositions containing alpha interferon
EP1449540A4
(en)
*
2001-11-02
2007-01-10
Sekisui Chemical Co Ltd
Cytokine-inducing material and cytokine-inducing instrument
US8137677B2
(en)
*
2005-10-06
2012-03-20
Allergan, Inc.
Non-protein stabilized clostridial toxin pharmaceutical compositions
EP2435139B1
(en)
*
2009-05-29
2016-10-05
Innonix Technologies, Incorporated
Composition for use in decreasing the transmission of human pathogens
RU2657535C2
(en)
*
2012-03-01
2018-06-14
Ферстстринг Рисерч, Инк.
Topical gels containing alpha connexin c-terminal (act) peptides
JP6081156B2
(en)
*
2012-11-15
2017-02-15
アルケア株式会社
Hydrogel
DE102012222365A1
(en)
2012-12-05
2014-06-05
Aesculap Ag
Composition for use in the prophylaxis of post-surgical adhesions
US20160120946A1
(en)
*
2013-06-09
2016-05-05
Efranat Ltd.
Compositions comprising gc-macrophage activating factor and uses thereof
US11252960B2
(en)
2017-01-31
2022-02-22
Kimberly-Clark Worldwide, Inc.
Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
Family Cites Families (8)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU1234383A
(en)
*
1982-03-17
1983-09-22
Inter-Yeda Ltd.
Interferon stabilised with polyvinyl-pyrrolidone
JPS6061535A
(en)
*
1983-08-24
1985-04-09
エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト
Pharmaceutical composition
JPS6069037A
(en)
*
1983-09-26
1985-04-19
Sunstar Inc
External preparation for erythematosus
DE3484951D1
(en)
*
1983-10-14
1991-09-26
Sumitomo Pharma
EXTENDED PREPARATIONS WITH DELAYED DELIVERY.
US4680175A
(en)
*
1984-02-07
1987-07-14
Interferon Sciences, Inc.
Interferon administration vehicles
CA1248450A
(en)
*
1984-04-05
1989-01-10
Kazuo Kigasawa
Soft patch
JPS60228422A
(en)
*
1984-04-26
1985-11-13
Suntory Ltd
Stabilized preparation of physiologically active substance
JPS60260523A
(en)
*
1984-06-07
1985-12-23
Asahi Chem Ind Co Ltd
Lyophilized drug composition of interferon
1986
1986-02-05
DE
DE19863603444
patent/DE3603444A1/en
not_active
Withdrawn
1987
1987-01-21
AT
AT87100792T
patent/ATE63823T1/en
not_active
IP Right Cessation
1987-01-21
ES
ES198787100792T
patent/ES2028796T3/en
not_active
Expired – Lifetime
1987-01-21
DE
DE8787100792T
patent/DE3770280D1/en
not_active
Expired – Fee Related
1987-01-21
EP
EP87100792A
patent/EP0231816B1/en
not_active
Expired – Lifetime
1987-02-03
FI
FI870457A
patent/FI86144C/en
not_active
IP Right Cessation
1987-02-03
DD
DD87299676A
patent/DD284602A5/en
not_active
IP Right Cessation
1987-02-03
CA
CA000528832A
patent/CA1295242C/en
not_active
Expired – Lifetime
1987-02-04
JP
JP62024423A
patent/JPS62209024A/en
active
Pending
1987-02-04
IL
IL81472A
patent/IL81472A0/en
not_active
IP Right Cessation
1987-02-04
IE
IE29587A
patent/IE59697B1/en
not_active
IP Right Cessation
1987-02-04
HU
HU87385A
patent/HU196560B/en
not_active
IP Right Cessation
1987-02-04
AU
AU68292/87A
patent/AU601712B2/en
not_active
Ceased
1987-02-04
PT
PT84243A
patent/PT84243B/en
not_active
IP Right Cessation
1987-02-04
NZ
NZ219169A
patent/NZ219169A/en
unknown
1987-02-04
NO
NO870441A
patent/NO169638C/en
unknown
1987-02-04
ZA
ZA87793A
patent/ZA87793B/en
unknown
1987-02-04
DK
DK058387A
patent/DK164202C/en
not_active
IP Right Cessation
1987-02-05
KR
KR870000912A
patent/KR870007698A/en
not_active
Application Discontinuation
1987-02-05
PH
PH34815A
patent/PH24377A/en
unknown
1991
1991-07-08
GR
GR91400966T
patent/GR3002270T3/en
unknown
Cited By (3)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU615473B2
(en)
*
1987-09-17
1991-10-03
Boehringer Ingelheim International Gmbh
Stabilisation of therapeutically active proteins in a pharmaceutical composition
WO1993006856A1
(en)
*
1991-10-11
1993-04-15
Mark Cedric Gillies
Treating ophthalmic fibrosis using interferon-alpha
US5863530A
(en)
*
1991-10-11
1999-01-26
Spruson & Ferguson
Treating ophthalmic fibrosis using interferon-α
Also Published As
Publication number
Publication date
NO870441D0
(en)
1987-02-04
DE3770280D1
(en)
1991-07-04
HU196560B
(en)
1988-12-28
AU601712B2
(en)
1990-09-20
ES2028796T3
(en)
1992-07-16
FI86144C
(en)
1992-07-27
IE59697B1
(en)
1994-03-23
EP0231816A2
(en)
1987-08-12
DK58387A
(en)
1987-08-06
DK58387D0
(en)
1987-02-04
PT84243A
(en)
1987-03-01
NZ219169A
(en)
1990-04-26
NO169638B
(en)
1992-04-13
DE3603444A1
(en)
1987-08-06
NO870441L
(en)
1987-08-06
JPS62209024A
(en)
1987-09-14
ZA87793B
(en)
1988-10-26
ATE63823T1
(en)
1991-06-15
CA1295242C
(en)
1992-02-04
EP0231816A3
(en)
1987-09-23
FI870457A
(en)
1987-08-06
GR3002270T3
(en)
1992-12-30
KR870007698A
(en)
1987-09-21
NO169638C
(en)
1992-07-22
IL81472A0
(en)
1987-09-16
HUT43494A
(en)
1987-11-30
IE870295L
(en)
1987-08-05
FI870457A0
(en)
1987-02-03
DK164202B
(en)
1992-05-25
PH24377A
(en)
1990-06-13
PT84243B
(en)
1989-09-14
DD284602A5
(en)
1990-11-21
DK164202C
(en)
1992-10-19
FI86144B
(en)
1992-04-15
EP0231816B1
(en)
1991-05-29
Similar Documents
Publication
Publication Date
Title
AU6829287A
(en)
1987-08-06
Stabilised formulations of alpha-interferon
HK1040631A1
(en)
2002-06-21
Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues.
AU7076887A
(en)
1987-10-29
Nasal administration of drugs
AU2724292A
(en)
1993-04-29
Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
CA2058428A1
(en)
1990-07-07
Analgesic formulations
IL85523A
(en)
1992-11-15
Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ES2009216A6
(en)
1989-09-16
IL-1alpha derivatives and drugs.
IL89748A
(en)
1993-07-08
Pharmaceutical compositions for systemic transdermal administration, containing deprenyl
TW234691B
(en)
1994-11-21
IL68456A0
(en)
1983-07-31
Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
AU1518492A
(en)
1992-06-25
Pharmaceutical compositions for transcutaneous administration
AU2231688A
(en)
1989-03-23
Stabilisation of therapeutically active proteins in a pharmaceutical composition
IL78604A
(en)
1991-11-21
Process for the preparation of homogeneous,pure alpha-interferon,alpha-interferon produced thereby and pharmaceutical compositions containing it
IE56229B1
(en)
1991-05-22
2-piperazinyl-or-homopiperazinyl-quinazoline derivatives their production and pharmaceutical compositions containing them
IL106289A0
(en)
1994-04-12
Phospholipid derivatives, their preparation and pharmaceutical compositions containing them
MY104088A
(en)
1993-11-30
Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
EP0355899A3
(en)
1991-03-20
Nucleotide derivatives
ES2091571T3
(en)
1996-11-01
NEW ACTIVE PEPTIDIC DERIVATIVES IN THE CELL ADHESION PROCESSES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
WO2001018039A3
(en)
2001-05-25
INCREASED PRODUCTION OF INTERFERON-$g(a)
AU4005993A
(en)
1993-12-09
New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them
IT8819541D0
(en)
1988-02-25
PHARMACEUTICAL COMPOSITION FOR NASAL ADMINISTRATION.
IL81926A0
(en)
1987-11-30
Pharmaceutical compositions for the oral administration of active proteins
IT8448979A1
(en)
1986-04-09
USE OF HYALURONIC ACID AS A VEHICLE FOR OPHTHALMIC DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THIS SUBSTANCE.
None